PolQi2: Potent DNA Polymerase Theta Inhibitor for Research

PolQi2 is a selective small-molecule inhibitor of DNA Polymerase Theta (Pol θ, encoded by POLQ), designed to block theta-mediated end joining (TMEJ) and support mechanistic studies in DNA repair and cancer biology.

Product Name

PolQi2

SKU

P1424598

Primary Target

DNA Polymerase Theta (Pol θ / POLQ)

Mechanism of Action

Selective inhibition of Pol θ ATPase/helicase or polymerase domain, blocking TMEJ DNA repair pathway

Key Research Application

BRCA1/2-deficient tumor models, synthetic lethality studies, DNA damage response

Reference Cross-ID

MCE-TJY: HY-150279

Background: DNA Polymerase Theta and TMEJ

DNA Polymerase Theta (Pol θ), encoded by the POLQ gene, is a multifunctional enzyme involved in an alternative DNA double-strand break (DSB) repair pathway known as Theta-Mediated End Joining (TMEJ), also referred to as microhomology-mediated end joining (MMEJ). Unlike high-fidelity repair pathways such as homologous recombination (HR) and non-homologous end joining (NHEJ), TMEJ is an error-prone process that exploits short microhomologous sequences flanking DSB sites to ligate broken DNA ends.

Pol θ is overexpressed in multiple human cancers and correlates with poor clinical prognosis. Importantly, HR-deficient tumors — including those harboring BRCA1 or BRCA2 mutations — become heavily dependent on TMEJ for survival, establishing Pol θ as an attractive synthetic lethal target in oncology research. Inhibition of Pol θ selectively kills HR-deficient cancer cells while sparing normal HR-proficient cells, a concept that underpins the therapeutic rationale for Pol θ inhibitor development.

PolQi2: Mechanism of Action

PolQi2 is a selective small-molecule inhibitor targeting DNA Polymerase Theta. By binding to and inhibiting the enzymatic activity of Pol θ, PolQi2 disrupts the TMEJ repair pathway, preventing the error-prone ligation of DNA double-strand breaks. This results in the accumulation of unrepaired DSBs and subsequent induction of cell death, particularly in cells that are already compromised in HR-mediated repair.

The compound is cross-referenced under MCE-TJY catalog number HY-150279, facilitating comparison with published literature and complementary reagent sourcing. Researchers using PolQi2 should validate inhibitory activity using established cellular or biochemical Pol θ assays appropriate to their experimental model systems.

Research Applications

PolQi2 is suitable for a range of research applications centered on DNA damage response and cancer biology:

• Synthetic Lethality Studies: Evaluate the selective toxicity of Pol θ inhibition in BRCA1- or BRCA2-deficient cell lines compared with isogenic HR-proficient controls.
• DNA Repair Pathway Dissection: Use PolQi2 alongside HR and NHEJ inhibitors to delineate the contribution of TMEJ to overall DSB repair in various genomic contexts.
• Cancer Biology: Investigate the role of TMEJ in maintaining genomic instability and mutagenesis in tumor models with elevated Pol θ expression.
• Combination Studies: Explore potential synergy between PolQi2 and PARP inhibitors, platinum-based agents, or other DNA-damaging compounds in preclinical cancer models.
• Target Validation: Confirm on-target cellular effects of Pol θ inhibition using appropriate genetic controls (e.g., POLQ knockout or knockdown cell lines).

Handling, Storage, and Experimental Considerations

As with all small-molecule research reagents, proper handling and storage of PolQi2 are essential to maintain compound integrity and experimental reproducibility. General recommendations for small-molecule inhibitors of this class include:

• Store lyophilized or powder forms at −20 °C, protected from light and moisture, unless the product datasheet specifies otherwise.
• Prepare stock solutions in DMSO (or the solvent specified on the datasheet) and aliquot to avoid repeated freeze-thaw cycles.
• Monitor DMSO vehicle concentration in cell-based assays; typically keep ≤0.1% to minimize cytotoxic artefacts.
• Include appropriate positive controls (e.g., known Pol θ inhibitors) and negative controls (vehicle-only) in all experiments.
• Confirm lot-specific purity and activity data from the Certificate of Analysis (CoA) prior to experimental use.

Refer to the product-specific datasheet and Safety Data Sheet (SDS) for authoritative storage conditions, solubility data, and safety information specific to PolQi2 (SKU P1424598).

Frequently asked questions

What is the primary molecular target of PolQi2?

PolQi2 selectively targets DNA Polymerase Theta (Pol θ), the enzyme encoded by the POLQ gene that is essential for the Theta-Mediated End Joining (TMEJ) DNA repair pathway. Inhibition of Pol θ disrupts this error-prone DSB repair route.

Why is PolQi2 relevant to BRCA-deficient cancer research?

BRCA1/2-mutant tumors are deficient in homologous recombination and become highly dependent on TMEJ for DNA double-strand break repair. PolQi2 exploits this dependency through synthetic lethality: inhibiting Pol θ in HR-deficient cells leads to catastrophic genomic instability and cell death while sparing HR-proficient normal cells.

What solvent is recommended for preparing PolQi2 stock solutions?

DMSO is commonly used for preparing stock solutions of small-molecule Pol θ inhibitors; however, researchers should consult the product-specific datasheet for PolQi2 (SKU P1424598) to confirm the recommended solvent, solubility, and concentration guidance for their specific lot.

How does PolQi2 compare to other Pol θ inhibitors in the literature?

PolQi2 is cross-referenced as HY-150279 in the MCE-TJY catalog, which may assist researchers in locating published data associated with this compound. For detailed selectivity profiles and potency comparisons, consult the product CoA and relevant peer-reviewed literature reporting on this compound class.

Can PolQi2 be used in combination with PARP inhibitors?

Combination studies with PARP inhibitors represent a scientifically rational approach given the overlapping reliance of HR-deficient tumors on alternative repair pathways. Researchers are encouraged to design appropriate dose-response and synergy assays; however, specific combination data for PolQi2 should be confirmed against published experimental evidence or generated empirically.

References

1. Yousefzadeh MJ et al. Mechanism of suppression of chromosomal instability by DNA polymerase POLQ. PLoS Genetics, 2014.
2. Mateos-Gomez PA et al. Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination. Nature, 2015.
3. Zatreanu D et al. Polθ inhibitors elicit BRCA-gene synthetic lethality and target BRCA-deficient tumours. Nature Communications, 2021.
4. MCE-TJY product entry HY-150279 (PolQi2). MedChemExpress internal reference. Cross-referenced SKU P1424598, Aladdin Scientific.

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.